David Young - 08 Jul 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
08 Jul 2021
Transactions value $
$0
Form type
4
Filing time
09 Jul 2021, 16:33:12 UTC
Previous filing
23 Jun 2021
Next filing
09 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +8,572 $0 8,572 08 Jul 2021 Common Stock 8,572 $0 Direct F1
transaction PCSA Restricted Stock Units Award $0 +12,858 $0 12,858 08 Jul 2021 Common Stock 12,858 $0 Direct F2
transaction PCSA Restricted Stock Units Award $0 +1,907 +23.46% $0 10,034 08 Jul 2021 Common Stock 10,034 $0 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units vest in two equal installments beginning July 1, 2022.
F2 The Restricted Stock Units vest upon achievement of certain performance goals.
F3 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.